HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>The "14th Five-year Plan" for the development of pharmaceutical industry was released. China's attention to the internationalization development of the pharmaceutical industry has risen to a new height.</li>
<li>There are still many real clinical needs that need to be addressed through innovation. So, this requires a change in thinking and a broadening of cognitive boundaries.</li>
<li>For some biotech, it is very difficult to have successful commercialization without differentiating products. Companies have to know how to “define” a good product,which is the right way to innovate.</li>
</ul>


The "14th Five-year Plan" for the development of pharmaceutical industry was released. China's attention to the internationalization development of the pharmaceutical industry has risen to a new height.
There are still many real clinical needs that need to be addressed through innovation. So, this requires a change in thinking and a broadening of cognitive boundaries.
For some biotech, it is very difficult to have successful commercialization without differentiating products. Companies have to know how to “define” a good product,which is the right way to innovate.


China Healthcare Weekly (Feb.4)- "14th Five-Year Plan" Of Pharmaceuticals, the Right Way to Innovate

Equity Bottom-Up

<ul>
<li>China attaches great importance to gene therapy and related products, which would be a leader of the third industrial revolution in biomedicine and have broad prospects for future development.</li>
<li>With obvious strength in this field,<a href="https://www.smartkarma.com/entities/genscript-biotech-corp" target="_blank" data-smartkarma-citation="entities:21041:1" rel="noopener">Genscript Biotech (1548 HK)</a>’s businesses are in line with the future trend and the outlook is also quite promising, indicating exponential growth potential in valuation.</li>
<li>However, the potential risks on deterioration of international relations and the concerns on CAR-T commercialization should not be neglected by investors.</li>
</ul>


China attaches great importance to gene therapy and related products, which would be a leader of the third industrial revolution in biomedicine and have broad prospects for future development.
With obvious strength in this field,Genscript Biotech (1548 HK)’s businesses are in line with the future trend and the outlook is also quite promising, indicating exponential growth potential in valuation.
However, the potential risks on deterioration of international relations and the concerns on CAR-T commercialization should not be neglected by investors.


Genscript Biotech (1548.HK) - The Strength and the Concerns

Porton Pharma Solutions / Equity Bottom-Up

<ul>
<li>Porton made a successful turnaround and the CGT business layout is also in the right direction. The US$217 million new order would improve the certainties of its 2022 performance.</li>
<li>The concerns on potential deterioration of international relations and the broken logic in CXO sector also apply to <a href="https://www.smartkarma.com/entities/porton-pharma-solutions-ltd" target="_blank" data-smartkarma-citation="entities:14201:1" rel="noopener">Porton Pharma Solutions (300363 CH)</a>, which should be aware of by investors.</li>
<li>So, there is a long way to go for Porton to truly get into the first tier. It may not be a good buying point currently considering the high valuation.</li>
</ul>


Porton made a successful turnaround and the CGT business layout is also in the right direction. The US$217 million new order would improve the certainties of its 2022 performance.
The concerns on potential deterioration of international relations and the broken logic in CXO sector also apply to Porton Pharma Solutions (300363 CH), which should be aware of by investors.
So, there is a long way to go for Porton to truly get into the first tier. It may not be a good buying point currently considering the high valuation.


Porton Pharma Solutions (300363.CH) - Not Easy to Get into the First Tier

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

LG Energy Solution / Equity Capital Markets

<ul>
<li><strong>Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. </strong></li>
<li>Trading debuts across different markets have been poor. But there are some trades to be put for lock-up expiries.</li>
<li>This will be our last week of ECM weekly notes for the year. Our weekly notes will be back in January when things start to pick up again.</li>
</ul>


Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. 
Trading debuts across different markets have been poor. But there are some trades to be put for lock-up expiries.
This will be our last week of ECM weekly notes for the year. Our weekly notes will be back in January when things start to pick up again.


ECM Weekly (19th December 2021) - LG Energy, Hyundai Engineering, Chervon, Sirnaomics, JG Mag A/H

Legend Biotech Corp / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/legend-biotech-corp" target="_blank" data-smartkarma-citation="entities:28963:1" rel="noopener">Legend Biotech Corp (LEGN US)</a> a non-wholly owned subsidiary of Hong Kong-listed <a href="https://www.smartkarma.com/entities/genscript-biotech-corp" target="_blank" data-smartkarma-citation="entities:21041:1" rel="noopener">Genscript Biotech (1548 HK)</a>, is looking US$300m in its follow-on offering.</li>
<li>The company was only listed in June 2020. It has traded well since IPO, about 111% up from its IPO price as of Tuesday’s close price. </li>
<li>But its offering was untimely, coinciding with the US blacklist that was just announced today.</li>
</ul>



Legend Biotech Corp (LEGN US) a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is looking US$300m in its follow-on offering.
The company was only listed in June 2020. It has traded well since IPO, about 111% up from its IPO price as of Tuesday’s close price. 
But its offering was untimely, coinciding with the US blacklist that was just announced today.


Legend Biotech (传奇生物) Follow-On Offering - Untimely Raise

China

Legend Biotech Corporation operates as a biopharmaceutical company. The Company engages in discovery and development of novel cell therapies for oncology and other indications. Legend Biotech serves customers in the State of New Jersey.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Legend Biotech Corp (LEGN US)

China Healthcare Weekly (Feb.4)- "14th Five-Year Plan" Of Pharmaceuticals, the Right Way to Innovate

We analyzed important points of the "14th Five-year Plan" for pharmaceutical industry. Meanwhile, the right way to innovate requires a broadening...

Xinyao (Criss) Wang

Genscript Biotech (1548.HK) - The Strength and the Concerns

This insight analyzed Genscript's three largest segments (life-science services and products, CDMO, cell therapy), strength in CGT, and concerns on...

Xinyao (Criss) Wang

Porton Pharma Solutions (300363.CH) - Not Easy to Get into the First Tier

This insight analyzed Porton about its past development, how it successfully made turnarounds, the future outlook, and concerns on deterioration of...

Xinyao (Criss) Wang

ECM Weekly (19th December 2021) - LG Energy, Hyundai Engineering, Chervon, Sirnaomics, JG Mag A/H

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Sumeet Singh

Legend Biotech (传奇生物) Follow-On Offering - Untimely Raise

Legend Biotech Corp (LEGN US) a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is looking US$300m in its follow-on...

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)